Prohibitin ligands: a growing armamentarium to tackle cancers, osteoporosis, inflammatory, cardiac and neurological diseases.
Fiche publication
Date publication
février 2020
Journal
Cellular and molecular life sciences : CMLS
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DESAUBRY Laurent
Tous les auteurs :
Wang D, Tabti R, Elderwish S, Abou-Hamdan H, Djehal A, Yu P, Yurugi H, Rajalingam K, Nebigil CG, Désaubry L
Lien Pubmed
Résumé
Over the last three decades, the scaffold proteins prohibitins-1 and -2 (PHB1/2) have emerged as key signaling proteins regulating a myriad of signaling pathways in health and diseases. Small molecules targeting PHBs display promising effects against cancers, osteoporosis, inflammatory, cardiac and neurodegenerative diseases. This review provides an updated overview of the various classes of PHB ligands, with an emphasis on their mechanism of action and therapeutic potential. We also describe how these ligands have been used to explore PHB signaling in different physiological and pathological settings.
Mots clés
Alzheimer disease, Autoimmune disease, C-RAF, Cancer, Cardiac diseases, Cardio-oncology, Cell signaling, Drug discovery, Inflammation, KRAS, LC3, MAP kinase, Melanogenesis, Mitophagy, NF-kB, Osteoclastogenesis, Osteoporosis, Parkinson disease, RAF1, Scaffold proteins, Wnt
Référence
Cell. Mol. Life Sci.. 2020 Feb 15;: